Large reductions in hsCRP appeared to foretell improved outcomes. An important CANTOS trial substudy bolsters evidence that inflammation plays an independent role in cardiovascular disease (CVD) and may point toward a new targeted approach to treatment of CVD and perhaps even more profoundly impact cancer treatment. Canakinumab is a monoclonal antibody that targets IL-1ß and ...
Ischaemic heart disease
CANTOS substudy shows major role for inflammation
By Larry Husten
16 Nov 2017